Skin cancer vaccine BLA submitted by...?

According to the latest prediction market data for the query “Skin cancer vaccine BLA submitted by...?”, traders have formed a strong consensus.

Currently, June 30, 2027? is dominating the market with an overwhelming 75.5% chance of winning. March 31, 2027 follows in second place at 53.5%. The betting volume for this specific market has already reached $90.7K, reflecting intense industry interest.

To better assess where each potential outcome stands, the market can be segmented into three distinct trading tiers based on implied probability and contract pricing:

🥇 Tier 1: The Dominant Leader

• June 30, 2027? (75.5%): Currently commanding the highest probability, June 30, 2027? is heavily favored by the order book. Traders looking to back this outcome face a “Buy Yes” contract price of 76¢, signaling a high degree of market conviction. This contract alone has generated $71.6K in volume.

🥈 Tier 2: The Primary Challengers

• March 31, 2027 (53.5%): Positioned as the most viable alternative, March 31, 2027 maintains a 53.5% chance of resolving true. Its “Buy Yes” shares currently trade at 54¢.

This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No".

Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.

A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication.

A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof.

The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify.

If the FDA grants approval of intismeran autogene on or before June 30, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed.

The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.

While human consensus and speculative volume shape the broader prediction market, our quantitative algorithms offer a data-driven counter-perspective. By analyzing fundamental signals, underlying trends and historical distributions, our AI Valuation model calculates an independent “Fair Value” probability for each outcome.

Comparing this Fair Value against the current Trade Value uncovers major disparities — known as the Expected Value (EV) Gap. Contracts with a positive EV Gap represent statistically underpriced outcomes, whereas a negative EV Gap flags a potential market overreaction.

Top AI Alpha & Mispriced Arbitrage Opportunities

Based on the latest data model run, several key contracts stand out with significant deviations:

• The Most Overvalued Outcome March 31, 2027 currently trades at 53.5%, but our AI places its Fair Value at just 50%. This creates a large negative EV Gap of -3.6%, suggesting the crowd may be overhyping this outcome and driving the premium too high.
• The Best Value Play (Highest EV) Our model identifies June 30, 2027? as the premium value opportunity on the board. While the market only assigns it a 75.5% trading probability, our AI’s Fair Value assessment sits at 83.6% — yielding an impressive +8.1% EV Gap.